advanced malignant solid tumors
Conditions
Sponsors
Chongqing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old male and female; 2. The expected survival period is =3 months; 3. Advanced malignant solid tumors confirmed by histopathology; 4. ECOG PS: 0-2 points; 5. Bone marrow, liver and kidney function are normal; 6. Subjects voluntarily participated in this study, signed informed consent, followed up with good compliance.
Exclusion criteria
Exclusion criteria: 1. Coagulation dysfunction, bleeding tendency (APTT greater than 1.5ULN or INR > 1.5), such as active peptic ulcer, or receiving thrombolysis or anticoagulant therapy; 2. The following severe concomitant diseases may cause greater risk or affect the compliance of the test: (1) Grade 2 hypertension with uncontrollable drug; (2) Grade III-IV cardiac insufficiency; (3) severe arrhythmia; (4) severe liver and kidney dysfunction; (5) urinary protein = ++, 24 hours Urine protein>1.0g; (6) chronic hepatitis; (7) mental illness; 3. Other anti-VEGF/VEGFR targeted drugs have been used before; 4. Patients who have undergone major surgery and have not healed in the past month; 5. Women during pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate;Objective remission rate;Quality of Life; | — |
Countries
China
Contacts
Public ContactYing Wang
Chongqing Cancer Hospital
Outcome results
None listed